Keywords: Celgene, Revlimid, USA, FDA, Malignancies, Ne Ph III, Disease progression
US FDA warns on safety of Celgene's Revlimid; new Ph III trial results
Article | 11 May 2012
The US Food and Drug Administration this week issued a notification of an increased risk of second primary malignancies (new ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
